Tech Company Financing Transactions
March Biosciences Funding Round
March Biosciences closed a $28.4 million Series A investment round on 10/23/2024. Investors included 4BIO Capital, Mission BioCapital and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
10/23/2024
Transaction Type
Venture Equity
Amount
$28,400,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support Phase 2 development of its lead CD5 CAR-T therapy, MB-105, for T-cell lymphoma and pipeline candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe boulevard X37
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Undisclosed
Website
Email Address
Overview
March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sarah Hein
Co-Founder
Max Mamonkin
Browse more venture capital transactions:
Prev: 10/23/2024: California Catalysts venture capital transaction
Next: 10/23/2024: Moneybox venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs